Recently, ziltivekimab, a novel anti-IL-6 ligand antibody, was tested in phase I/II randomized clinical trial of 61 HD patients with a single nucleotide polymorphism of the TMPRSS6 gene, which is known to increase the effects of IL-6 on inflammation, elevated IL-6, and hyporesponse to ESA therapy [86]. The gene discussed is IL6; the disease is Huntington disease.